FDA Inspection 1308158 — Barbara Steinborn, M.D.
The FDA completed an inspection of Barbara Steinborn, M.D. on March 5, 2026 in Poznan. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 5, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Poznan (Poland)
Additional Details
Clinical Investigator (CI)